- Home
- TLSA vs EYEN Comparison
TLSA vs EYEN Comparison
Compare TLSA & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- EYEN
- Stock Information
- Founded
- TLSA 2013
- EYEN 2014
- Country
- TLSA United Kingdom
- EYEN United States
- Employees
- TLSA N/A
- EYEN N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- EYEN Health Care
- Exchange
- TLSA Nasdaq
- EYEN Nasdaq
- Market Cap
- TLSA 87.8M
- EYEN 38.2M
- IPO Year
- TLSA 2000
- EYEN 2018
- Fundamental
- Price
- TLSA $1.20
- EYEN $0.55
- Analyst Decision
- TLSA
- EYEN Strong Buy
- Analyst Count
- TLSA 0
- EYEN 2
- Target Price
- TLSA N/A
- EYEN $12.00
- AVG Volume (30 Days)
- TLSA 145.8K
- EYEN 879.0K
- Earning Date
- TLSA 05-10-2024
- EYEN 11-11-2024
- Dividend Yield
- TLSA N/A
- EYEN N/A
- EPS Growth
- TLSA N/A
- EYEN N/A
- EPS
- TLSA N/A
- EYEN N/A
- Revenue
- TLSA N/A
- EYEN $31,405.00
- Revenue This Year
- TLSA N/A
- EYEN $50,309.30
- Revenue Next Year
- TLSA N/A
- EYEN $421.63
- P/E Ratio
- TLSA N/A
- EYEN N/A
- Revenue Growth
- TLSA N/A
- EYEN N/A
- 52 Week Low
- TLSA $0.41
- EYEN $0.37
- 52 Week High
- TLSA $1.74
- EYEN $2.57
- Technical
- Relative Strength Index (RSI)
- TLSA 65.44
- EYEN 52.60
- Support Level
- TLSA $0.83
- EYEN $0.52
- Resistance Level
- TLSA $0.92
- EYEN $0.59
- Average True Range (ATR)
- TLSA 0.09
- EYEN 0.05
- MACD
- TLSA 0.03
- EYEN 0.01
- Stochastic Oscillator
- TLSA 84.52
- EYEN 66.45
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.